ReviewJournal of mid-life health
Impact of Proton Pump Inhibitors on Blood Glucose in Type 2 Diabetes: A Systematic Review with Meta-analysis.
Review in Journal of mid-life health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton pump inhibitors (PPIs) are widely prescribed for acid-related disorders, but emerging evidence suggests they may influence glucose metabolism. This meta-analysis evaluates the effect of PPIs on glycemic control in patients with and without type 2 diabetes mellitus (T2DM). We systematically searched PubMed, Cochrane Library, Embase, and Scopus for randomized controlled trials and observational studies reporting fasting blood glucose (FBG), HbA1c, or insulin resistance with PPI use. Risk of bias was assessed using the Cochrane RoB 2.0 tool for randomized trials and the Newcastle-Ottawa Scale for observational studies. Data were synthesized using a random-effects model and expressed as mean differences with 95% confidence intervals (CIs). The review was not prospectively registered in PROSPERO or any other database. Fifteen studies involving 2,038 participants were included in the study. PPI use significantly reduced FBG (mean decrease: 5.32 mg/dL; 95% CI: 2.01-8.63;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.